Kenneth Pittman
Long only, value, biotech, healthcare

Cytokinetics Still Has Value, Despite Setbacks

Quick Background:

I am a Physician (practicing Child Psychiatry) and I have been an investor in Cytokinetics (NASDAQ:CYTK) for approximately 16 months. While this is my first Seeking Alpha article, I have contributed my thoughts more briefly to StockTwits during that time. I intend to contribute more regularly to Seeking Alpha as a way of more fully explaining my ideas. While CYTK is one of my more prominent holdings, I follow several other Biotech stocks as well as some technical/value plays.

Two Studies Which Did Not Meet Primary End Point

Omecamtiv Mecarbil ATOMIC Study

ATOMIC-AHF was a Phase 2b study of an IV form of Omecamtiv Mecarbil (OM) for which results were presented at the European Society of...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details